New breakthrough in LED lighting: Philips pushes new medical products to deal with psoriasis

Psoriasis, also known as psoriasis, is an incurable skin disease. Scaly red patches will appear when the disease occurs, and the surface layer of the skin will fall off at the same time. It is reported that the lighting industry giant Philips (Philips) The company is about to introduce a new BlueControl device, an LED light-emitting component that can help patients with mild and moderate psoriasis to control their illness. What is important is that it will not produce any side effects. Research shows that blue LED light can play a certain role in curbing cowhide freshness. Its root cause lies in the rapid division of cells, which is the basis for BlueControl's research and development. In addition, it can also effectively control skin inflammation. Philips has designed a low-key binding component for BlueControl, which can provide energy for batteries. Patients can fix them in various parts of the body to relieve the disease. BlueControl systems do not use conventional LED light, mainly because they do not necessarily meet the needs of medical grade. In order to develop high-intensity LED light modulated by pulses, Philips has jointly completed the research with academic and clinical partners. Philips and University Hospital of Aachen, Germany ( UniversityHospitalofAachen) Jointly tested BlueControl. Of the two clinical trials, the second lasted for four months and officially ended in June 2014. PASI index showed that the patient's symptoms decreased by an average of 50. PASI index can measure the severity of psoriatic plaque from the aspects of thickness, redness and expansion. In addition, clinical trials also found that blue LED light does not produce any side effects. The European Society for Dermatology and sexually transmitted diseases will be held in Amsterdam from October 8-12, 2014. At that time, Philips will show its newly developed BlueControl for the first time. Subsequently, the equipment will be listed in the Netherlands, Germany and the United Kingdom.